These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32880761)

  • 21. Utility of remission criteria for the renal prognosis of IgA nephropathy.
    Matsuzaki K; Suzuki H; Kawamura T; Tomino Y; Suzuki Y
    Clin Exp Nephrol; 2021 Sep; 25(9):988-995. PubMed ID: 33974158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal outcome after tonsillectomy plus corticosteroid pulse therapy in patients with immunoglobulin A nephropathy: results of a multicenter cohort study.
    Hoshino J; Fujii T; Usui J; Fujii T; Ohashi K; Takaichi K; Suzuki S; Ubara Y; Yamagata K
    Clin Exp Nephrol; 2016 Aug; 20(4):618-627. PubMed ID: 26577676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cohort study of advanced IgA nephropathy: efficacy and limitations of corticosteroids with tonsillectomy.
    Sato M; Hotta O; Tomioka S; Horigome I; Chiba S; Miyazaki M; Noshiro H; Taguma Y
    Nephron Clin Pract; 2003; 93(4):c137-45. PubMed ID: 12759582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Steroid pulse therapy transiently destroys the discriminative histological structure of tonsils in IgA nephropathy: Tonsillectomy should be performed before or just after steroid pulse therapy.
    Adachi M; Sato M; Miyazaki M; Hotta O; Hozawa K; Sato T; Taguma Y; Katori Y
    Auris Nasus Larynx; 2018 Dec; 45(6):1206-1213. PubMed ID: 29789195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of corticosteroid therapy for IgA nephropathy patients stratified by kidney function and proteinuria.
    Nagasawa Y; Yamamoto R; Shinzawa M; Shoji T; Hasuike Y; Nagatoya K; Yamauchi A; Hayashi T; Kuragano T; Moriyama T; Isaka Y
    Clin Exp Nephrol; 2020 Oct; 24(10):927-934. PubMed ID: 32642919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of methods of steroid administration combined with tonsillectomy for IgA nephropathy patients.
    Watanabe H; Goto S; Kondo D; Takata T; Yamazaki H; Hosojima M; Yamamoto S; Kaneko Y; Aoyagi R; Narita I
    Clin Exp Nephrol; 2017 Apr; 21(2):257-265. PubMed ID: 27216016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and limitations of additional steroid pulse therapy in IgA nephropathy patients whose hematuria did not remit on tonsillectomy and protocol steroid pulse therapy.
    Toda M; Kume A; Hara M; Kimura H; Nakamura Y; Okumura K; Beppu H; Nakamura Y; Ogawa H; Kamei Y; Ishiwatari A; Kawanishi T; Ogawa T; Abe Y; Endo M; Wakai S
    Clin Exp Nephrol; 2022 Sep; 26(9):859-866. PubMed ID: 35486336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study.
    Komatsu H; Fujimoto S; Hara S; Sato Y; Yamada K; Kitamura K
    Clin J Am Soc Nephrol; 2008 Sep; 3(5):1301-7. PubMed ID: 18508946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy.
    Miura N; Imai H; Kikuchi S; Hayashi S; Endoh M; Kawamura T; Tomino Y; Moriwaki K; Kiyomoto H; Kohagura K; Nakazawa E; Kusano E; Mochizuki T; Nomura S; Sasaki T; Kashihara N; Soma J; Tomo T; Nakabayashi I; Yoshida M; Watanabe T
    Clin Exp Nephrol; 2009 Oct; 13(5):460-466. PubMed ID: 19449181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tonsillectomy reduces recurrence of IgA nephropathy in mesangial hypercellularity type categorized by the Oxford classification.
    Hirano K; Amano H; Kawamura T; Watanabe K; Koike K; Shimizu A; Endo S; Tsuboi N; Okonogi H; Miyazaki Y; Ikeda M; Hanaoka K; Ogura M; Komatsumoto S; Yokoo T
    Clin Exp Nephrol; 2016 Jun; 20(3):425-32. PubMed ID: 26415960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of hematuria on the outcome of IgA nephropathy with mild proteinuria.
    Tanaka K; Moriyama T; Iwasaki C; Takei T; Nitta K
    Clin Exp Nephrol; 2015 Oct; 19(5):815-21. PubMed ID: 25475403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multivariate analysis of prognostic factors and effect of treatment in patients with IgA nephropathy.
    Komatsu H; Fujimoto S; Hara S; Sato Y; Yamada K; Eto T; Nakao H
    Ren Fail; 2005; 27(1):45-52. PubMed ID: 15717634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of tonsillectomy combined with steroid pulse therapy on immunoglobulin A nephropathy depending on histological classification: a multicenter study.
    Miyamoto T; Nishino T; Nakata T; Sato Y; Komatsu H; Uramatsu T; Ishimatsu N; Ishida K; Serino R; Otsuji Y; Miyazaki M; Tomo T; Tamura M; Fujimoto S
    Clin Exp Nephrol; 2016 Feb; 20(1):50-7. PubMed ID: 26055039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum IgA/C3 ratio: a useful marker of disease activity in patients with IgA nephropathy.
    Torikoshi K; Endo T; Tsukamoto T; Yasuda T; Yasuda Y; Kawamura T; Matsuo S; Suzuki Y; Muso E
    Int Urol Nephrol; 2024 Oct; 56(10):3389-3396. PubMed ID: 38829466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tonsillectomy and steroid pulse therapy for IgA nephropathy.
    Moriyama T; Nitta K
    Tohoku J Exp Med; 2011 Aug; 224(4):243-50. PubMed ID: 21705849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tonsillectomy for IgA nephropathy: a meta-analysis.
    Liu LL; Wang LN; Jiang Y; Yao L; Dong LP; Li ZL; Li XL
    Am J Kidney Dis; 2015 Jan; 65(1):80-7. PubMed ID: 25446024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-treatment hematuria and crescents predict estimated glomerular filtration rate trajectory after methylprednisolone pulse therapy with tonsillectomy for IgA nephropathy.
    Nagai M; Kobayashi N; Izumi N; Ohbayashi T; Hotta O; Hamano T
    J Nephrol; 2022 Mar; 35(2):441-449. PubMed ID: 34014510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early intensive therapy for clinical remission of active IgA nephropathy: a three-year follow-up study.
    Hotta O; Taguma Y; Kurosawa K; Sudo K; Suzuki K; Horigome I
    Nihon Jinzo Gakkai Shi; 1993 Aug; 35(8):967-73. PubMed ID: 8255008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics of IgA nephropathy in advanced-age patients.
    Oshima Y; Moriyama T; Itabashi M; Takei T; Nitta K
    Int Urol Nephrol; 2015 Jan; 47(1):137-45. PubMed ID: 25388352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nationwide survey on current treatments for IgA nephropathy in Japan.
    Matsuzaki K; Suzuki Y; Nakata J; Sakamoto N; Horikoshi S; Kawamura T; Matsuo S; Tomino Y
    Clin Exp Nephrol; 2013 Dec; 17(6):827-33. PubMed ID: 23519367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.